STOCK TITAN

Bolt Biotherapeutics (BOLT) Stock News, Oct 2023-Sep 2024

BOLT NASDAQ

Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.

Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, has announced changes to its Board of Directors. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, has been appointed to the board, bringing over 20 years of experience in oncology and immuno-oncology. Concurrently, Dr. Jim Healy is stepping down as Lead Independent Director, Frank D. Lee is departing the board, and Brian O'Callaghan, CEO of Deep Genomics, will assume the role of Chair.

Dr. Dupont's extensive background includes leadership roles at Atara Biotherapeutics, Gossamer Bio, and Genentech/Roche, where he was instrumental in developing several successful cancer therapies. His appointment is expected to benefit Bolt's pipeline advancement and collaborations. The company is currently conducting a clinical trial with a first-in-class Dectin-2 agonist and has a near-clinical ISAC program targeting Claudin 18.2.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
management
-
Rhea-AI Summary

Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, has announced its participation in two major conferences this September. The company will be featured in:

1. A fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 7:00 a.m. EDT.

2. A company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, available from September 9, 2024, at 7:00 a.m. EDT.

Both presentations will be accessible via webcast on Bolt's website, with replays available for 30 days after each event. This participation demonstrates Bolt's commitment to engaging with investors and showcasing its progress in the competitive field of cancer immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Advancement to cohort 6 in the Phase 1 study of BDC-3042 for advanced cancers.

2. Acceptance of an abstract for BDC-4182, a claudin 18.2-targeting Boltbody ISAC, at the SITC 39th Annual Meeting.

3. Cash balance of $97.5 million as of June 30, 2024, expected to fund operations through mid-2026.

4. Q2 2024 financial results: Collaboration revenue of $1.3 million, R&D expenses of $15.4 million, G&A expenses of $4.9 million, and a loss from operations of $22.6 million.

5. Ongoing collaborations with Genmab and Toray continue to progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced its Q1 2024 financial results, revealing a strategic pipeline prioritization and leadership changes. The company will focus on its Phase 1 Dectin-2 agonist antibody BDC-3042 and its next-gen Boltbody™ ISAC platform, including the new clinical candidate BDC-4182 targeting Claudin 18.2. Development of trastuzumab imbotolimod (BDC-1001) will halt, and the workforce will be cut by approximately 50% to extend the cash runway into the second half of 2026.

Willie Quinn replaces Randall Schatzman as CEO, with other leadership promotions announced. Financially, Bolt reported collaboration revenue of $5.3 million, up from $1.8 million in Q1 2023, and a loss from operations of $17.1 million, down from $18.4 million the previous year. R&D expenses increased to $16.5 million, driven by higher clinical trial costs. G&A expenses rose slightly to $5.8 million. The company will host a webcast to discuss these changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.12%
Tags
management earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.00%
Tags
conferences

FAQ

What is the current stock price of Bolt Biotherapeutics (BOLT)?

Bolt Biotherapeutics (BOLT) last closed at $5.65.

What is the market cap of Bolt Biotherapeutics (BOLT)?

The market cap of Bolt Biotherapeutics (BOLT) is approximately $14.7M.